Asuragen Names Colin Hill Senior Vice President of Commercial Operations
Austin, Texas – February 10, 2016 – Asuragen, Inc., a global molecular diagnostics company, announced today that it has appointed Colin Hill as Senior Vice President of Commercial Operations. Colin will lead the product commercialization strategy including business development, sales, marketing, scientific affairs and technical services.
“Colin is joining Asuragen at a key moment as we accelerate the pace of diagnostic product development, companion diagnostic partnerships and commercial expansion worldwide,” commented Matt McManus, President and CEO. “His global commercial experience in the diagnostics industry is a great addition to the Company and positions us for this next phase of exciting growth.”
Colin brings to Asuragen over 20 years of diagnostic commercial leadership, and was most recently Vice President of the Platform Business Unit at Ortho Clinical Diagnostics, a laboratory diagnostics company with a broad range of instruments and menu serving multiple clinical disciplines from clinical chemistry and immunoassay to donor screening applications. He previously held multiple international technical and commercial roles in the molecular diagnostics space at Bayer & Siemens Healthcare Diagnostics culminating in leading the North American Molecular Biology & Microbiology business. Colin received a B.Sc. (HONS) in Immunology from The University of Edinburgh (UK) and a M.Sc. in Molecular Pathology & Toxicology from the University of Leicester (UK).
“I am thrilled to join Asuragen – a company at the cutting edge of science that is delivering high impact diagnostic products,” said Colin Hill. “Their commitment to quality science, robust products and stream-lined workflows will truly drive precision medicine forward and build the future of health care.”
View our Leadership Team
Asuragen is a global diagnostic products company delivering solutions that build knowledge and understanding of complex clinical questions. Asuragen’s application of its deep scientific heritage and molecular expertise delivers diagnostic products in oncology and genetics that provide the best answers with optimal workflows – so time can be spent delivering actionable insights, rather than searching for them. With innovative approaches to kit development and a broad range of molecular chemistries, Asuragen produces assays that ensure reproducible results. From discovery and development to regulatory support to global commercialization, we also provide a tailored approach that efficiently delivers custom and companion diagnostic products for our partners. We believe people deserve better answers. For more information, visit www.asuragen.com.
SVP, Corporate Development and Chief Financial Officer